HOLD ACC. Strong Performance on Better Volume and Firm Realizations. Target Price: Rs1,640. Institutional Equity Research

Similar documents
CMP (Rs) 775 Upside/ (Downside) (%) (1.4) Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7

HOLD. Nestle. Good Performance Irrespective of GST Pangs. Target Price: Rs6,624. Institutional Equity Research. 2QCY17 Result Update July 27,2017

CMP* (Rs) 1,458 Upside/ (Downside) (%) 10 Bloomberg Ticker. ABB IN Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212

CMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630

Nestlé India Outlook Hazy; Valuations Prohibitive

CMP* (Rs) 242 Upside/ (Downside) (%) 2. Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630

CMP* (Rs) 166 Upside/ (Downside) (%) 28 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245

CMP* (Rs) 336 Upside/ (Downside) (%) 21 Bloomberg Ticker. MOIL IN Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133

BUY NCC. An Ordinary Quarterly Performance; Maintain BUY. Target Price: Rs98. Institutional Equity Research. 4QFY17 Result Update May 24, 2017

CMP* (Rs) 1,424 Upside/ (Downside) (%) 19 Bloomberg Ticker Market Cap. (Rs bn) 268 Free Float (%) 46 Shares O/S (mn) 188

CMP* (Rs) 263 Upside/ (Downside) (%) 7.3. Market Cap. (Rs bn) 635 Free Float (%) 59 Shares O/S (mn) 2,417

CMP* (Rs) 840 Upside/ (Downside) (%) (2.4) Bloomberg Ticker Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6

Titan Company BUY. Back to Value Zone Validate Rating Upgrade. Institutional Equity Research. November 05, Target Price Rs428.

CMP* (Rs) 417 Upside/ (Downside) (%) 46 Bloomberg Ticker. SUNP IN Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399

CMP* (Rs) 205 Upside/ (Downside) (%) 12 Bloomberg Ticker. NACO IN Market Cap. (Rs bn) 29 Free Float (%) 27 Shares O/S (mn) 143

CMP* (Rs) 161 Upside/ (Downside) (%) 19 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,329 Free Float (%) 30.3 Shares O/S (mn) 8,245

CMP* (Rs) 203 Upside/ (Downside) (%) 23. Market Cap. (Rs bn) 116 Free Float (%) 61 Shares O/S (mn) 572

CMP* (Rs) 346 Upside/ (Downside) (%) 17. Market Cap. (Rs bn) 23 Free Float (%) 42.0 Shares O/S (mn) 67

CMP* (Rs) 237 Upside/ (Downside) (%) 29 Bloomberg Ticker. APTY IN Market Cap. (Rs bn) 136 Free Float (%) 55.9 Shares O/S (mn) 509

CMP* (Rs) 360 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 38 Free Float (%) 76 Shares O/S (mn) 104.5

CMP (Rs) 326 Upside/ (Downside) (%) 24. Market Cap. (Rs bn) 21.7 Free Float (%) 42.0 Shares O/S (mn) 67

CMP* (Rs) 1,033 Upside/ (Downside) (%) (0.3) Bloomberg Ticker Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452

CMP* (Rs) 172 Upside/ (Downside) (%) 11.6 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,414 Free Float (%) 30.3 Shares O/S (mn) 8,245

CMP (Rs) 702 Upside/ (Downside) (%) 42 Bloomberg Ticker. JKCE IN Market Cap. (Rs bn) 54 Free Float (%) 42 Shares O/S (mn) 77.3

CMP (Rs) 133 Upside/ (Downside) (%) 35 Bloomberg Ticker. ICEM IN Market Cap. (Rs bn) 41 Free Float (%) 71.6 Shares O/S (mn) 308.1

BUY CDSL. Strong Operating Performance; Maintain BUY. Target Price: Rs435. Institutional Equity Research. 2QFY18 Result Update October 31, 2017

BUY NTPC. Higher Regulated Equity to Aid Profitability; Maintain BUY. Target Price: Rs192. Institutional Equity Research

CMP* (Rs) 1,464 Upside/ (Downside) (%) 10. Market Cap. (Rs bn) 91 Free Float (%) 55 Shares O/S (mn) 62

CMP (Rs) 249 Upside/ (Downside) (%) Market Cap. (Rs bn) 25.5 Free Float (%) 29.7 Shares O/S (mn) 102.3

KNR Constructions Robust Performance on Execution Ramp-up

BUY. DCB Bank. Improving Capital Consumption to Aid Returns; Maintain BUY. Target Price: Rs202. Institutional Equity Research

CMP* (Rs) 289 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) 30 Free Float (%) 69 Shares O/S (mn) 105

CMP* (Rs) 145 Upside/ (Downside) (%) 32 Bloomberg Ticker BOB IN Market Cap. (Rs bn) 384 Free Float (%) 36 Shares O/S (mn) 2,646

Sonata Software HOLD. Unimpressive Show; IITS Revenue Disappoints. Institutional Equity Research. February 06, Target Price Rs190.

CMP* (Rs) 198 Upside/ (Downside) (%) 12. Market Cap. (Rs bn) 61 Free Float (%) 84 Shares O/S (mn) 308

CMP* (Rs) 189 Upside/ (Downside) (%) (1) Bloomberg Ticker PNB IN Market Cap. (Rs bn) 402 Free Float (%) 38 Shares O/S (mn) 2,128

CMP (Rs) 166 Upside/ (Downside) (%) (1) Bloomberg Ticker Market Cap. (Rs bn) 125 Free Float (%) 37 Shares O/S (mn) 726

CMP* (Rs) 301 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 19.6 Free Float (%) 26 Shares O/S (mn) 65

ACC BUY. Performance Highlights. CMP `1,397 Target Price `1,630. 3QCY2015 Result Update Cement

Aurobindo Pharma. Institutional Equity Research. Sector - Pharmaceuticals. RSec TradEdge India. March 02, 2017

Ambuja Cements ACCUMULATE. Performance Highlights. CMP Target Price `207 `233. 3QCY2015 Result Update Cement. Quarterly results (Standalone)

Jubilant FoodWorks. Institutional Equity Research. Sector - FMCG. RSec TradEdge India. January 17, 2017

EBITDA 5,076 3, , EBITDA

BUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E

Ambuja Cements NEUTRAL. Performance Highlights CMP. `184 Target Price - 2QCY2012 Result Update Cement. Quarterly results (Standalone)

Balkrishna Industries

Amber Enterprises India Ltd

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance

Garware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months

Religare Investment Call

Institutional Equities

Ambuja Cements NEUTRAL. Performance Highlights CMP. `155 Target Price - 1QCY2011 Result Update Cement. Investment Period - Key financials (Standalone)

HOLD. Margins to improve from Q2 AMBUJA CEMENTS. Target Price: Rs 232. Other highlights

Consolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE

Goodyear India ACCUMULATE. Performance Highlights. CMP Target Price `326 `374. 1QCY2012 Result Update Tyres. Key financials

ACC NEUTRAL. Performance Highlights. CMP `1,261 Target Price - 4QCY2012 Result Update Cement. Quarterly results (Standalone) Investment Period -

Visaka Industries Ltd

Hindustan Media Ventures

ITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months

Blue Star Ltd BUY. Performance Update. CMP Target Price `703 `867. 1QFY2019 Result Update Cons. Durable. 3-year price chart.

Inox Wind BUY. Performance Highlights. CMP Target Price `242 `286. 4QFY2016 Result Update Capital Goods. 3 year price chart

Hindustan Unilever (RHS)

Key estimate revision. Year CY14 87,383 11,148 6, CY15E 1,20,126 17,838 9,

Power Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution

Strides Arcolab. Inline 4Q, recent acquisitions to deepen asset growth. Institutional Equity Research. Strides Arcolab. Pharmaceuticals India

Mahindra & Mahindra Ltd.

Colgate-Palmolive (India)

BUY. White cement steals the show JK CEMENT. Target Price: Rs 1,220. Other highlights

Maruti Suzuki India BUY. Performance Update. CMP `6,705 Target Price `8,552. 2QFY2019 Result Update Automobile. Historical share price chart

Mahindra & Mahindra Ltd.

ACC Ltd. BUY CMP (Rs.) 1,471 Target (Rs.) 1,655 Potential Upside 13% For private circulation only. Volume No.. II Issue No. 172.

Religare Investment Call

KEC International. Recovering from a weak phase. Institutional Equity Research. Order inflow traction remains intact

Amara Raja Batteries BUY. Performance Highlights. CMP `1,010 Target Price `1,167. 2QFY2017 Result Update Auto Ancillary. 3-year price chart

Dalmia Bharat Enterprises

Fineotex Chemical Ltd

CY16 CY17 CY18E CY19E

Asian Granito BUY. Performance Highlights CMP. `270 Target Price `351. Outlook and valuation. 3QFY2017 Result Update Ceramics

Transport Corporation of India Ltd.

Tata Steel BUY. Performance Highlights. 3QFY2010 Result Update I Steel

Transport Corporation of India Ltd.

Simplex Infrastructures

Nestlé India. Q2CY17 Result Update. Positives priced in; Downgrade to Hold. Sector: FMCG CMP: ` 6,786. Recommendation: HOLD

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Sanofi India. Institutional Equities. 3QCY18 Result Update. Robust Performance BUY

TTK Prestige Ltd. Result Highlights. Revenue growth of 41% YoY, shows no slowdown yet. OPM at ~15.8%; in line with our estimate

Ambuja Cements NEUTRAL. Performance Highlights. Outlook and Valuation. 4QCY2009 Result Update I Cement

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015

Gillette India. Institutional Equities. 1QFY18 Result Update

Weak numbers in peak quarter

GMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months

Ahluwalia Contracts (India)

Goodyear India BUY. Company Update. CMP Target Price `515 `631. Company Update Tyres. 3-year Daily Price Chart. Key Financials

Ambuja Cement. Realisations-driven beat SELL RESULTS REVIEW 2QCY17 25 JUL Highlights of the quarter

Bloomberg Code: ATA IN

Rallis India SELL. Performance Highlights. `231 Target Price 189 CMP. 2QFY2018 Result Update Agrichemical. Investment Period 12 months

EBITDA 6,223 6,511 (4.4) 5, EBITDA

Ramco Cement. Rating: Target price: EPS: Rating CMP. Target BUY. Rs.415. Rs. 360

Procter & Gamble Hygiene & Health Care

Bata India BUY. Performance Update. CMP Target Price `842. 1QFY2019 Result Update Footwear. Historical share price chart.

Transcription:

2QCY17 Result Update July 18,2017 Market Cap. (Rs bn) 328 Free Float (%) 45 Shares O/S (mn) 188 Strong Performance on Better Volume and Firm Realizations reported better-than-estimated performance in 2QCY17 with its EBITDA per tonne surpassing Rs700-mark for the first time in the last eight quarters and stood at Rs715 vs. our estimate of Rs684. Operating profit grew by 20% YoY and 45% QoQ to Rs4.95bn vs. our expectation of Rs4.65bn. Better-than-estimated sales volume growth (+10.1% YoY and +2.1% QoQ) and firm increase in average realizations (+6.7% YoY and +5.0% QoQ) aided operating performance. Notably, operating cost per tonne for cement rose by 3% YoY to Rs3,881 (flat on QoQ basis) mainly due to hardening of fuel prices and spike in transportation cost. However, production ramp-up from the Jamul plant and better usage of raw material and fuel-mix aided to contain the cost to a considerable extent. Going forward, we foresee sales volume growth to remain stellar due to improved utilization from the newly commissioned units along with better demand outlook post monsoon. However, realizations may witness some pressure owing to GST roll-out and Government s possible intervention in the medium term. We cut our EBITDA estimate by 7% and 1% for CY17E and CY18E, respectively mainly to factor in likely pressure on realizations (as channel check suggests) in the medium term. We maintain our recommendation on the stock with a revised Target Price of Rs1,640. Better Sales Volume Aids Revenue Reported revenue stood at Rs33.1bn (+17% YoY) topping our estimate of Rs32.6bn mainly on account of better-than-expected sales volume. Sales volume for the quarter stood at 6.74mnT (+10.1% YoY). A healthy demand scenario in key markets and production ramp-up from Jamul plant enabled to register stellar volume growth. We envisage to record sales volume growth of 11% and 9% in CY17E and CY18E, respectively. Healthy Operating Performance Led by Volume & Realization Up-tick Operating profit grew by 20% YoY and 45% QoQ to Rs4.95bn vs. our expectation of Rs4.65bn. Better-than-expected sales volume growth (+10.1% YoY and +2.1% QoQ) and increase in average realization (+6.7% YoY and +5.0% QoQ) aided operating performance. Notably, operating cost per tonne for cement rose by 3% YoY to Rs3,881 (flat on QoQ basis) mainly due to hardening of fuel prices and spike in transportation cost. EBITDA per tonne stood at Rs715 compared to Rs657 and Rs497 in 2QCY16 and 1QCY17, respectively. Valuation & Outlook We continue to maintain our positive view on due to its deep penetration in rural markets and strong brand equity. Though we cut our EBITDA estimates, we increase our target EV/ EBITDA multiple from 11x to 12x on the back of a) likely merger with Ambuja Cement that may drive its valuations, b) revival in rural demand which will aid due to extensive rural base and c) visible improvement in operating synergies. Hence, we maintain our recommendation on the stock with a revised Target Price of Rs1,640. Key Financials (Rs mn) CY15 CY16 CY17E CY18E Sales 114,328 109,364 127,381 144,020 EBITDA 11,731 11,951 16,399 24,228 APAT 6,010 5,739 9,454 14,382 EPS (Rs) 32.0 30.5 50.3 76.5 DPS (Rs) 1.7 1.7 1.7 1.7 P/E (x) 54.6 57.2 34.7 22.8 P/B (x) 3.9 3.8 3.6 3.2 EV/EBIDTA (x) 26.8 26.2 19.1 12.9 RoE (%) 7.1 7.0 10.6 14.8 Div. Yield (%) 1.0 1.0 1.0 1.0 Source: Company, RSec Research Share price (%) 1 mth 3 mth 12 mth Absolute performance 6.6 16.2 8.3 Relative to Nifty 3.2 7.7 (7.8) Shareholding Pattern (%) Mar'17 Jun'17 Promoter 54.5 54.5 Public 45.5 45.5 1 Year Stock Price Performance 1,800 1,700 1,600 1,500 1,400 1,300 1,200 1,100 1,000 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Note: * CMP as on July 17, 2017 Research Analyst: Binod Modi Contact: 022 3320 1097 Email: binod.modi@relianceada.com 1

Risks to the View ff Government s failure to revive infrastructure projects. ff Significant surge in operating cost and dip in realizations. Exhibit 1: Quarterly Performance (Rs mn) 2QCY17 2QCY16 % yoy 1QCY17 % qoq 1HCY17 1HCY16 % yoy Net Sales 33,125 28,326 16.9 30,997 6.9 64,122 57,053 12.4 (Increase)/Decrease in stock in trade (1,022) 641 (259.5) 42 (2,516.3) (980) 724 (235.4) Consumption of RM 5,038 4,097 23.0 4,605 9.4 9,642 8,461 14.0 Purchase of Traded goods 3 14 (81.1) 2 28.6 5 18 (73.3) % sales 12.1 16.8 15.0 13.5 Employee cost 2,182 1,859 17.4 1,952 11.8 4,134 3,682 12.3 % sales 6.6 6.6 6.3 6.4 6.5 Power & Fuel 6,847 5,222 31.1 6,477 5.7 13,323 10,894 22.3 % sales 20.7 18.4 20.9 20.8 19.1 Freight Outward 8,753 6,539 33.9 8,304 5.4 17,058 13,871 23.0 % sales 26.4 23.1 26.8 26.6 24.3 Other Expenditures 6,374 5,817 9.6 6,197 2.9 12,571 11,480 9.5 % sales 19.2 20.5 20.0 19.6 20.1 Total Expenditures 28,175 24,190 16.5 27,579 2.2 55,753 49,129 13.5 Operating cost/tonne (Rs) 4,180 3,953 5.8 4,179 0.0 4,179 3,937 6.2 EBIDTA 4,951 4,136 19.7 3,418 44.8 8,369 7,924 5.6 EBIDTA per tonne (Rs) 715 657 9.0 497 44.0 607 615 (1.3) EBIDTA Margin 14.9 14.6 11.0 13.1 13.9 Depreciation 1,621 1,410 15.0 1,650 (1.8) 3,271 2,844 15.0 Interest 225 208 8.3 252 (10.6) 477 396 20.5 Other Income 1,663 730 127.8 1,101 51.1 2,764 1,848 49.6 PBT 4,768 3,248 46.8 2,617 82.2 7,385 6,532 13.1 Margin Tax Expenses 1,550 824 88.1 502 209.0 2,052 1,761 16.5 % PBT 32.5 25.4 19.2 PAT 3,217 2,424 32.7 2,115 52.1 5,333 4,770 11.8 Net margin 9.7 8.6 6.8 8.3 8.4 APAT 3,217 2,424 32.7 2,115 52.1 5,333 4,770 11.8 EPS (Rs) 17.1 12.9 32.8 11.3 52.2 28.4 25.4 11.8 Source: Company, RSec Research 2

Exhibit 2: Revised v/s Old Estimates Rs mn CY17E CY18E Old Revised % change Old Revised % change Volume (mnt) 25.0 25.6 2.3 27.6 27.9 1.2 Realization (Rs/tonne) 4,690 4,569 (2.6) 4,877 4,752 (2.6) Sales (Rs mn) 127,809 127,381 (0.3) 145,916 144,020 (1.3) EBITDA (Rs mn) 17,680 16,399 (7.2) 24,412 24,228 (0.8) EBITDA/tonne (Rs) 707 642 (9.3) 886 869 (1.9) APAT (Rs mn) 9,646 9,454 (2.0) 13,566 14,382 6.0 EPS (Rs) 51.3 50.3 (2.0) 72.2 76.5 6.0 Source: RSec Research 3

Profit & Loss Y/E Dec (Rs mn) CY15 CY16 CY17E CY18E Net Sales 114,328 109,364 127,381 144,020 % yoy growth (0.4) (4.3) 16.5 13.1 Total Cost 102,597 97,413 110,982 119,792 Raw Materials Cost 25,223 23,477 27,175 29,694 Employee Costs 7,699 7,783 8,770 9,772 Power & Fuel 23,941 21,571 24,974 27,803 Freight and Forwardings 27,230 26,547 30,398 31,519 Other Expenditures 18,505 18,036 19,666 21,004 EBITDA 11,731 11,951 16,399 24,228 EBIDTA Margin (%) 10.3 10.9 12.9 16.8 Depreciation and Amortisation 6,521 6,052 6,818 6,984 Interest 673 729 762 835 Other Income 4,834 3,346 4,685 5,153 Exceptional Items (1,532) (428) - - PBT 7,840 8,089 13,505 21,563 Tax 1,924 3,240 4,052 7,180 % Tax 24.5 40.1 30.0 33.3 Excep. Items - - - - Net Profit 5,916 6,024 9,454 14,382 YoY Growth (%) (49.4) 1.8 56.9 52.1 Net Profit Margin (%) 5.2 5.5 7.4 10.0 Adjusted Profit 6,010 5,739 9,454 14,382 4

Balance Sheet Y/E Dec (Rs mn) CY15 CY16 CY17E CY18E Share Capital 1,880 1,880 1,880 1,880 Reserves & Surplus 82,513 84,697 90,309 100,850 Total Shareholder's funds 84,393 86,577 92,189 102,730 Secured Loans - - - - Unsecured Loans 355 500 500 500 Total Debt 355 500 500 500 Deferred Tax Liability 4,692 5,581 5,581 5,581 TOTAL LIABILITIES 89,439 92,659 98,271 108,811 Gross Block 113,525 140,705 145,705 147,705 Less: Accumulated Depreciation 60,675 66,080 72,898 79,882 Net Block 52,850 74,624 72,806 67,822 CWIP 23,710 2,608 2,608 2,608 Investments 14,757 18,042 26,042 41,042 Other Non Current Assets 4,663 4,831 5,235 5,919 Inventories 11,886 12,238 13,262 14,994 Sundry Debtors 4,844 4,677 5,584 6,313 Cash & Bank 916 2,756 3,460 4,558 Other Current Assets 551 602 650 700 Loans & Advances 14,232 13,998 14,098 14,298 Total Current Assets 32,429 34,270 37,054 40,864 Current Liablities 31,339 34,300 36,924 39,889 Provisions 7,592 7,378 8,514 9,518 Net Current Assets (6,502) (7,409) (8,384) (8,543) Misc. Expenditure (38) (37) (37) (37) Total Assets 89,439 92,659 98,271 108,811 5

Cash Flow Statement Y/E Dec (Rs mn) CY15 CY16 CY17E CY18E PBT 7,840 8,089 13,505 21,563 Depreciation 6,521 6,052 6,818 6,984 Interest Paid 673 729 762 835 Others 1,289 (438) - - Oper Cash flow before WC changes 16,322 14,431 21,084 29,382 Change in Working Capital 579 2,088 1,680 1,257 Cash Generated from Operation 16,902 16,518 22,764 30,639 Direct Tax (net) (2,289) (2,717) (4,052) (7,180) Net Cash from Operating Activities 14,612 13,801 18,712 23,459 Purchase / Sale of Fixed Assets (net) (11,643) (4,976) (5,000) (2,000) Purchase of Investment (25) (1,357) (8,000) (15,000) Others 2,186 941 (404) (684) Net Cash in Investment activities (9,482) (5,391) (13,404) (17,684) Proceeds/ Repay of LT Borrowings (net) - - - - Proceed from issue of share capital - 2 - - Interest Paid (415) (478) (762) (835) Others (6,395) (3,736) (3,842) (3,842) Net cash in Financing activities (6,810) (4,212) (4,603) (4,677) Net incre / (decre) in cash equivalents (1,680) 4,199 705 1,098 Key Ratio Y/E Dec CY15 CY16 CY17E CY18E Valuation Ratio (x) P/E 54.6 57.2 34.7 22.8 P/CEPS 26.4 27.2 20.2 15.4 P/BV 3.9 3.8 3.6 3.2 EV/EBITDA 26.8 26.2 19.1 12.9 EV/Sales 2.8 2.9 2.5 2.2 EV/tonne (USD) 160 147 147 146 Dividend Payout (%) 54.0 53.0 33.8 0.2 Dividend Yield (%) 1.0 1.0 1.0 1.0 Per Share Data (Rs) EPS (Basic) 32.0 30.5 50.3 76.5 EPS (Diluted) 32.0 30.5 50.3 76.5 CEPS 66.2 64.2 86.6 113.7 DPS 1.7 1.7 1.7 1.7 Book Value 449 461 490.4 546.5 EBITDA/tonne 497 520 642 869 Returns (%) RoCE 9.6 9.7 14.9 21.6 RoE 7.1 7.0 10.6 14.8 Turnover ratios (x) Asset Turnover (Gross block) 1.0 0.8 0.9 1.0 Inventory (days) 37.9 40.8 38.0 38.0 Receivables (days) 15.5 15.6 16.0 16.0 Payables (days) 64.1 80.5 78.0 80.0 WCC (days) (10.7) (24.1) (24.0) (26.0) 6

Rating Guides Rating Expected absolute returns (%) over 12 months BUY >10% -5% to 10% REDUCE >-5% Reliance Securities Limited (RSL), the broking arm of Reliance Capital is one of the India s leading retail broking houses. Reliance Capital is amongst India s leading and most valuable financial services companies in the private sector. Reliance Capital has interests in asset management and mutual funds, life and general insurance, commercial finance, equities and commodities broking, wealth management services, distribution of financial products, private equity, asset reconstruction, proprietary investments and other activities in financial services. The list of associates of RSL is available on the website www.reliancecapital.co.in. RSL is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014 General Disclaimers: This Research Report (hereinafter called Report ) is prepared and distributed by RSL for information purposes only. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through RSL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security(ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by RSL to be reliable. RSL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of RSL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. Risks: Trading and investment in securities are subject to market risks. There are no assurances or guarantees that the objectives of any of trading / investment in securities will be achieved. The trades/ investments referred to herein may not be suitable to all categories of traders/investors. The names of securities mentioned herein do not in any manner indicate their prospects or returns. The value of securities referred to herein may be adversely affected by the performance or otherwise of the respective issuer companies, changes in the market conditions, micro and macro factors and forces affecting capital markets like interest rate risk, credit risk, liquidity risk and reinvestment risk. Derivative products may also be affected by various risks including but not limited to counter party risk, market risk, valuation risk, liquidity risk and other risks. Besides the price of the underlying asset, volatility, tenor and interest rates may affect the pricing of derivatives. Disclaimers in respect of jurisdiction: The possession, circulation and/or distribution of this Report may be restricted or regulated in certain jurisdictions by appropriate laws. No action has been or will be taken by RSL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/ or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. RSL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to RSL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India. Disclosure of Interest: The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the securities and their respective issuers. None of RSL, research analysts, or their relatives had any known direct /indirect material conflict of interest including any long/short position(s) in any specific security on which views/opinions have been made in this Report, during its preparation. RSL s Associates may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report. RSL, its Associates, the research analysts, or their relatives might have financial interest in the issuer company(ies) of the said securities. RSL or its Associates may have received a compensation from the said issuer company(ies) in last 12 months for the brokerage or non brokerage services.rsl, its Associates, the research analysts or their relatives have not received any compensation or other benefits directly or indirectly from the said issuer company(ies) or any third party in last 12 months in any respect whatsoever for preparation of this report. The research analysts has served as an officer, director or employee of the said issuer company(ies)?: No RSL, its Associates, the research analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies).?: No Copyright: The copyright in this Report belongs exclusively to RSL. This Report shall only be read by those persons to whom it has been delivered. No reprinting, reproduction, copying, distribution of this Report in any manner whatsoever, in whole or in part, is permitted without the prior express written consent of RSL. RSL s activities were neither suspended nor have defaulted with any stock exchange with whom RSL is registered. Further, there does not exist any material adverse order/judgments/ strictures assessed by any regulatory, government or public authority or agency or any law enforcing agency in last three years. Further, there does not exist any material enquiry of whatsoever nature instituted or pending against RSL as on the date of this Report. Important These disclaimers, risks and other disclosures must be read in conjunction with the information / opinions / views of which they form part of. RSL CIN: U65990MH2005PLC154052. SEBI registration no. ( Stock Brokers: NSE - INB / INF / INE 231234833; BSE - INB / INF / INE 011234839, Depository Participants: CDSL IN-DP-257-2016 IN-DP-NSDL-363-2013, Research Analyst: INH000002384); AMFI ARN No.29889. 7